Glaukos Ocular Drug Delivery Implant with Controlled Release
Summary
USPTO granted patent US12599497B2 to Glaukos Corporation on April 14, 2026, for an ocular drug delivery device with controlled drug release capabilities. The patent covers devices for treating ocular disorders through targeted administration of drugs to interior portions of the eye, with structures allowing treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber.
What changed
USPTO issued patent US12599497B2 to Glaukos Corporation covering drug delivery devices for treating ocular disorders. The patent includes claims for devices capable of controlled release of drugs and structures that permit aqueous humor to flow out of the anterior chamber through the device, allowing treatment of increased intraocular pressure.
For medical device manufacturers and pharmaceutical companies, this patent establishes intellectual property protection for Glaukos in the ocular drug delivery space. Competitors developing similar ophthalmic implants or drug delivery devices should review this patent to assess potential freedom-to-operate implications. The patent grants Glaukos exclusive rights to the disclosed technology in the United States for the duration of the patent term.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Implants with controlled drug delivery features and methods of using same
Grant US12599497B2 Kind: B2 Apr 14, 2026
Assignee
Glaukos Corporation
Inventors
David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
Abstract
Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
CPC Classifications
A61F 2250/0067 A61F 9/0017 A61F 9/00781
Filing Date
2023-01-09
Application No.
18151816
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Prosthetics (A61F)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Prosthetics (A61F) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.